Compare EPAM Systems Inc (EPAM) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Inovio Pharmaceuticals Inc — how do they compare? EPAM Systems Inc trades at $87.31 (market cap $4.49B), while Inovio Pharmaceuticals Inc trades at $1.13 (market cap $96.26M). The key difference: EPAM Systems Inc is far larger — about 46.6× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| EPAM | INO | |
|---|---|---|
Market Cap | $4.49B | $96.26M |
Sector | Technology | Health |
52-Week High | $221.40 | $2.87 |
52-Week Low | $76.04 | $1.05 |
Enterprise Value | $3.74B | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $88.59, up 4.84% today, with a bearish technical signal but strong fundamentals including a P/E of 12.35 and P/S of 0.86. Recent earnings beats and a consensus analyst price target of $128.55 suggest undervaluation, while cash flow trends show operational strength despite a net decline in 2026 projections. The stock faces headwinds from AI sector volatility but benefits from strategic partnerships and AI-native revenue growth.
The outlook for EPAM is cautiously optimistic, with significant upside potential based on analyst targets, though risks include competitive pressures and macroeconomic uncertainty. Investment opportunity lies in its valuation discount and digital engineering expertise, but investors should monitor execution on AI initiatives and sector sentiment shifts for near-term direction.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
